<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Diffusion Pharmaceuticals</title>
	<atom:link href="http://www.diffusionpharma.com/feed" rel="self" type="application/rss+xml" />
	<link>http://www.diffusionpharma.com</link>
	<description></description>
	<lastBuildDate>Fri, 16 Mar 2012 15:14:14 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Diffusion Pharmaceuticals Begins Clinical Trial for New Brain Cancer Drug</title>
		<link>http://www.diffusionpharma.com/research/braincancerclinicaltrial2012</link>
		<comments>http://www.diffusionpharma.com/research/braincancerclinicaltrial2012#comments</comments>
		<pubDate>Tue, 14 Feb 2012 15:55:22 +0000</pubDate>
		<dc:creator>Tracey Danner</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[brain cancer]]></category>
		<category><![CDATA[cancer treatment]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Diffusion Pharmaceuticals]]></category>
		<category><![CDATA[Emily Couric Cancer Center]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[GBM]]></category>
		<category><![CDATA[glioblastoma multiforme]]></category>
		<category><![CDATA[Orphan Drug Designation]]></category>
		<category><![CDATA[trans sodium crocetinate]]></category>
		<category><![CDATA[TSC]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[University of Virginia]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=486</guid>
		<description><![CDATA[Diffusion Pharmaceuticals LLC announced today that it has opened for enrollment a clinical trial testing the company’s lead drug candidate trans sodium crocetinate (TSC) as a first-line treatment for newly diagnosed primary brain cancer, also known as glioblastoma or GBM. Currently there is no cure for GBM and patients have an average life expectancy of [...]]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/research/braincancerclinicaltrial2012/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer</title>
		<link>http://www.diffusionpharma.com/research/fda-grants-orphan-drug-status-for-tsc-in-cancer</link>
		<comments>http://www.diffusionpharma.com/research/fda-grants-orphan-drug-status-for-tsc-in-cancer#comments</comments>
		<pubDate>Tue, 26 Jul 2011 14:32:05 +0000</pubDate>
		<dc:creator>Tracey Danner</dc:creator>
				<category><![CDATA[Awards]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[brain cancer]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Diffusion Pharmaceuticals]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[GBM]]></category>
		<category><![CDATA[glioblastoma multiforme]]></category>
		<category><![CDATA[Orphan Drug Designation]]></category>
		<category><![CDATA[trans sodium croctetinate]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=427</guid>
		<description><![CDATA[Charlottesville, VA – July 26, 2011 – Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company’s lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.  GBM is one of [...]]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/research/fda-grants-orphan-drug-status-for-tsc-in-cancer/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Diffusion Pharmaceuticals Closes on $2.2 Million Financing; Plans Clinical Trial In Primary Brain Cancer</title>
		<link>http://www.diffusionpharma.com/progress/closes-on-2-2-million-financing-plans-clinical-trial-in-primary-brain-cancer</link>
		<comments>http://www.diffusionpharma.com/progress/closes-on-2-2-million-financing-plans-clinical-trial-in-primary-brain-cancer#comments</comments>
		<pubDate>Sun, 01 May 2011 15:04:02 +0000</pubDate>
		<dc:creator>Tracey Danner</dc:creator>
				<category><![CDATA[Funding]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[fundraising]]></category>
		<category><![CDATA[GBM]]></category>
		<category><![CDATA[glioblastoma multiforme]]></category>
		<category><![CDATA[TSC]]></category>

		<guid isPermaLink="false">http://www.diffusionpharma.com/?p=439</guid>
		<description><![CDATA[CHARLOTTESVILLE, VA – May 1, 2011 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat life-threatening unmet medical conditions, today announced that it closed on an additional $2.2 million in private financing during the first quarter of 2011. The financing consisted of convertible notes issued to existing investors. Proceeds will support [...]]]></description>
		<wfw:commentRss>http://www.diffusionpharma.com/progress/closes-on-2-2-million-financing-plans-clinical-trial-in-primary-brain-cancer/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

